Illumina, Inc. (ILMN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$218.22-1.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · ILMN
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(9.1) + peer(0.2*8.6) + term(2.0) → 6.91% (capped ±15.0)
in 53 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On July 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 28, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t…
Results of Operations and Financial Condition. On April 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 29, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…
Results of Operations and Financial Condition. On February 5, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…
Results of Operations and Financial Condition. On January 13, 2026, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Illumina, Inc. (the "Company") issued a press release regarding the Company's unaudited preliminary financial results for the fourth quarter and fiscal year ended December 28, 2025. The webcast is accessible through the Investor Relations section of the Company’s website and will remain available for at least 30…
Results of Operations and Financial Condition. On October 30, 2025, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the third quarter ended September 28, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subje…
Results of Operations and Financial Condition. On July 31, 2025, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 29, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t…
Results of Operations and Financial Condition. On May 8, 2025, Illumina, Inc. (the "Company") issued a press release announcing financial results for the first quarter ended March 30, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the…
Results of Operations and Financial Condition. On February 6, 2025, Illumina, Inc. (the "Company") issued a press release announcing financial results for the fourth quarter and fiscal year ended December 29, 2024. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…
Results of Operations and Financial Condition. On January 14, 2025, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Illumina, Inc. (the "Company") issued a press release regarding the Company's unaudited preliminary financial results for the fourth quarter and fiscal year ended December 29, 2024. The webcast is accessible through the Investor Relations section of the Company’s website and will remain available for at least 30…
Results of Operations and Financial Condition. On November 4, 2024, Illumina, Inc. (the "Company") issued a press release announcing financial results for the third quarter ended September 29, 2024. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subje…
Results of Operations and Financial Condition. On August 6, 2024, Illumina, Inc. (the "Company") issued a press release announcing financial results for the second quarter ended June 30, 2024. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…
Results of Operations and Financial Condition. On May 2, 2024, Illumina, Inc. (the "Company") issued a press release announcing financial results for the first quarter ended March 31, 2024. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the…
by this reference. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.